With slow vaccine distribution and manufacturing, some people won’t get the second dose on time. But does it matter?
Articles on Pfizer
Displaying 81 - 100 of 116 articles
Australia is set to get the green light to roll out the Pfizer vaccine any day now. There is a complex process behind this.
Many countries cannot afford to buy existing COVID-19 vaccines, a collective approach is needed.
Researchers say around 70% of the US needs to get the coronavirus vaccine to stop the pandemic. But questions around the vaccines and regional differences add some uncertainty to that estimate.
So far, the only COVID-19 vaccines authorized for use need to be kept frozen. But there are many places in the world that can’t support a cold supply chain.
A new strain of the SARS-CoV-2 virus that causes COVID-19 appears to be spreading fast in the UK. This probably isn’t a big problem, but the data isn’t in yet.
COVID-19 vaccines have very specific storage requirements that make shipping a difficult task. Two ideas – fulfillment centers and cross-docking – could help overcome some distribution challenges.
We should applaud drug companies for developing COVID-19 vaccines in record time, but let’s not be under any illusion about the profits that are motivating them.
Millions of Americans say they won’t get the vaccine. Will money change their minds? And is luring them with cash the right approach?
COVID-19 vaccine testing on children is just getting started, and only in adolescents.
The vaccines that will first be used to prevent the spread of COVID-19 will have gone through a special approval process with the FDA. but just what is this expedited process?
The side effects of new SARS-CoV-2 vaccines are a result of immune system activation. While uncomfortable, they are both normal and expected. They are a sign that the vaccine is working.
‘Sensible’ public figures have far less influence on our behaviour than it seems
Because Pfizer-BioNTech and Moderna vaccines have been developed in record time, many wonder whether companies cut corners or compromised safety.
Pfizer and BioNTech have announced 95% efficacy for their mRNA vaccine, having met the final target they need to before seeking regulatory approval.
Two pharma companies have announced early COVID-19 vaccine trial results with over 90 per cent effectiveness. What does that mean for getting back to normal?
There are two new COVID-19 vaccines that appear to be more than 90% effective. But what are these vaccines, and how are they different from those used previously?
Moderna’s shot is far easier to store and distribute than Pfizer’s. But there are concerns neither vaccine performs particularly well for older people.
The recent vaccine trial results certainly look impressive, but here’s how to fully interrogate what they mean.
Interim analysis of trial data isn’t unusual – but leaves us with many things we still need to find out.
Top contributors
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor, The Children's Hospital at Westmead Clinical School and Sydney Infectious Diseases Institute, University of Sydney
-
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
-
Professor of Medicine, University of Virginia
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professorial Fellow, University of Canberra
-
Instructor of Human Immunology, Emory University
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor, Infectious Diseases and Microbiology, The University of Queensland
-
Professor of Paediatrics and vaccinologist, Royal Childrens Hospital, University of Melbourne and Murdoch Childrens Research Institute (MCRI); Associate Dean International, University of Melbourne, Murdoch Children's Research Institute
-
Pharmacist and PhD Candidate, University of Sydney
-
Pediatric Infectious Diseases Fellow, University of Pittsburgh
-
Professor of Pharmaceutical Chemistry, Macquarie University
-
Professor of Business, University of Michigan